Pharmacology, Toxicology and Pharmaceutical Science
Antiapoptotic
8%
Aortic Valve Stenosis
50%
Atrial Fibrillation
100%
Atrioventricular Block
6%
Beta Adrenergic Receptor Blocking Agent
50%
Biological Marker
58%
Bleeding
6%
Carcinogenicity
5%
Cardiogenic Shock
25%
Cardiovascular Disease
6%
Cardiovascular Risk
6%
Cohort Study
8%
Congestive Heart Failure
8%
Coronavirinae
50%
Diabetes Mellitus
8%
Disease
57%
Enzyme-Linked Immunosorbent Assay
8%
Ezetimibe
16%
Fibroblast Growth Factor 23
5%
Heart Arrhythmia
6%
Heart Atrium Remodeling
5%
Heart Infarction
50%
Heart Muscle Ischemia
8%
Heart Ventricle Remodeling
13%
Hospital Mortality
50%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
16%
Infarction
25%
Ischemic Cardiomyopathy
50%
Low Density Lipoprotein Cholesterol
41%
microRNA
50%
Monotherapy
8%
Non ST Segment Elevation Myocardial Infarction
50%
Paroxysmal Atrial Fibrillation
50%
Pathophysiology
7%
Persistent Atrial Fibrillation
50%
Prematurity
7%
Prevalence
8%
Protein P53
25%
Pulmonary Hypertension
50%
Random Effects Model
8%
Rat Model
8%
Recurrent Disease
50%
Retrospective Study
8%
Rivaroxaban
50%
Second Degree Atrioventricular Block
6%
Small Interfering RNA
16%
Somatomedin Binding Protein 2
50%
ST Segment Elevation Myocardial Infarction
50%
Statin (Protein)
8%
Sudden Cardiac Death
50%
Medicine and Dentistry
Adipose Tissue
5%
Aortic Valve Stenosis
50%
Arrhythmia
6%
Atrial Fibrillation
100%
Atrial Fibrillation Therapy
6%
Atrioventricular Block
6%
Biological Marker
50%
Bleeding
6%
Cardiovascular Condition
7%
Cardiovascular Disease
6%
Cardiovascular Risk
6%
Cardiovascular System
13%
Cardiovascular System
6%
Cardioversion
50%
Clinical Study
5%
Color Doppler Flowmetry
12%
Comorbidity
5%
COVID-19
50%
Diabetes Mellitus
8%
Diseases
7%
Drug Therapy
8%
Echocardiography
7%
Endothelial Dysfunction
5%
Ezetimibe
16%
Fibroblast Growth Factor 23
5%
Growth
5%
Logistic Regression Analysis
6%
Low Density Lipoprotein Cholesterol
41%
Lung Artery Pressure
21%
Major Bleeding
6%
Monotherapy
8%
Paroxysmal Atrial Fibrillation
50%
Pathophysiology
7%
Percutaneous Aortic Valve Replacement
21%
Persistent Atrial Fibrillation
50%
Prematurity
7%
Primary Prevention
8%
Propensity Score Matching
6%
Pulmonary Hypertension
50%
Recurrent Disease
50%
Retrospective Study
8%
Rivaroxaban
50%
Second-Degree Atrioventricular Block
6%
Secondary Prevention
16%
Somatomedin Binding Protein 2
50%
ST Segment Elevation Myocardial Infarction
50%
Statin
25%
Study Participant
7%
Sudden Cardiac Death
50%
Thromboprophylaxis
18%
